These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 31176759)
1. Adiponectin is required for pioglitazone-induced improvements in hepatic steatosis in mice fed a high-fat diet. de Mendonça M; Dos Santos BAC; de Sousa É; Rodrigues AC Mol Cell Endocrinol; 2019 Aug; 493():110480. PubMed ID: 31176759 [TBL] [Abstract][Full Text] [Related]
2. Pioglitazone Enhances Cytosolic Lipolysis, β-oxidation and Autophagy to Ameliorate Hepatic Steatosis. Hsiao PJ; Chiou HC; Jiang HJ; Lee MY; Hsieh TJ; Kuo KK Sci Rep; 2017 Aug; 7(1):9030. PubMed ID: 28831172 [TBL] [Abstract][Full Text] [Related]
4. Effects of calycosin against high-fat diet-induced nonalcoholic fatty liver disease in mice. Duan X; Meng Q; Wang C; Liu Z; Sun H; Huo X; Sun P; Ma X; Peng J; Liu K J Gastroenterol Hepatol; 2018 Feb; 33(2):533-542. PubMed ID: 28699662 [TBL] [Abstract][Full Text] [Related]
6. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472 [TBL] [Abstract][Full Text] [Related]
7. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD). Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942 [TBL] [Abstract][Full Text] [Related]
8. Probiotic culture supernatant improves metabolic function through FGF21-adiponectin pathway in mice. Liu Q; Liu Y; Li F; Gu Z; Liu M; Shao T; Zhang L; Zhou G; Pan C; He L; Cai J; Zhang X; Barve S; McClain CJ; Chen Y; Feng W J Nutr Biochem; 2020 Jan; 75():108256. PubMed ID: 31760308 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA miR-222 mediates pioglitazone beneficial effects on skeletal muscle of diet-induced obese mice. de Mendonça M; de Sousa É; da Paixão AO; Araújo Dos Santos B; Roveratti Spagnol A; Murata GM; Araújo HN; Imamura de Lima T; Passos Simões Fróes Guimarães DS; Silveira LR; Rodrigues AC Mol Cell Endocrinol; 2020 Feb; 501():110661. PubMed ID: 31770568 [TBL] [Abstract][Full Text] [Related]
10. Pioglitazone suppresses inflammation and fibrosis in nonalcoholic fatty liver disease by down-regulating PDGF and TIMP-2: Evidence from in vitro study. Deng W; Meng Z; Sun A; Yang Z Cancer Biomark; 2017 Dec; 20(4):411-415. PubMed ID: 28946547 [TBL] [Abstract][Full Text] [Related]
11. Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. Khaleel EF; Abdel-Aleem GA Arch Physiol Biochem; 2019 Feb; 125(1):64-78. PubMed ID: 29429367 [TBL] [Abstract][Full Text] [Related]
12. Effects of a low-fat diet on the hepatic expression of adiponectin and its receptors in rats with NAFLD. Ma H; You GP; Cui F; Chen LF; Yang XJ; Chen LG; Lu HD; Zhang WQ Ann Hepatol; 2015; 14(1):108-17. PubMed ID: 25536648 [TBL] [Abstract][Full Text] [Related]